INTENSIFICATION WITH INSULIN GLARGINE 300 U/ML (Gla-300) OR FIRST- GENERATION BASAL INSULINS (BIs) IN PEOPLE WITH TYPE 2 DIABETES (T2D) ON ONCE-WEEKLY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs): DELIVER NEW-G

被引：0
|
作者：
Umpierrez, G. [1 ]
Bailey, T. [2 ]
Mahieu, A. [3 ]
Li, X. [4 ]
Mabunay, M. A. [5 ]
Fonseca, V [6 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] AMCR Inst, Escondido, CA USA
[3] Sanofi, Paris, France
[4] Sanofi, Bridgewater, NJ USA
[5] Sanofi, Singapore, Singapore
[6] Tulane Univ, Med Ctr, New Orleans, LA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE139
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [21] Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review
    Guo, Xia
    Yang, Qing
    Dong, Jianjun
    Liao, Lin
    Zhang, Weiwei
    Liu, Fupeng
    CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 433 - 441
  • [22] Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review
    Xia Guo
    Qing Yang
    Jianjun Dong
    Lin Liao
    Weiwei Zhang
    Fupeng Liu
    Clinical Drug Investigation, 2016, 36 : 433 - 441
  • [23] Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry-The REALITY Study
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Sauriol, Luc
    Aronson, Ronnie
    DIABETES, 2018, 67
  • [24] Cost of introducing once weekly semaglutide among other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of Type 2 diabetes: A UK budget impact analysis
    Hoxer, C. S.
    DIABETIC MEDICINE, 2019, 36 : 169 - 169
  • [25] Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
    Sreenivasan, Chithra
    Parikh, Aneri
    Francis, Aida J.
    Kanthajan, Tatchaya
    Pandey, Manorama
    Alqassab, Osamah
    Nath, Tuheen Sankar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [26] Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)
    Harris, Stewart B.
    Snoek, Frank J.
    Meneghini, Luigi
    Lauand, Felipe, Sr.
    Westerbacka, Jukka
    de Climens, Aude Roborel
    Khunti, Kamlesh
    DIABETES, 2020, 69
  • [27] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D plus Subgroup Analyses
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    DIABETES, 2018, 67
  • [28] High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the US Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk)
    Sullivan, Sean D.
    Freemantle, Nick
    Menon, Arjun A.
    Gupta, Rishab
    Wu, Jasmanda
    Nicholls, Charlie
    Westerbacka, Jukka
    Bailey, Timothy S.
    DIABETES, 2019, 68
  • [29] Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
    Wright, Eugene
    Gill, Jasvinder
    Huse, Samuel
    Li, Xuan
    Reid, Timothy
    Zhou, Fang L.
    DIABETES, 2021, 70
  • [30] Risk of Gastroparesis Is Higher with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) but Risk of Death Is Higher with Insulin Glargine in Veterans with Type 2 Diabetes and CKD
    Sarwal, Amara
    Singh, Ravinder
    Wei Guo
    Hartsell, Sydney Elizabeth
    Boucher, Robert E.
    Nevers, Mckenna R.
    Katkam, Niharika
    Takyi, Augustine
    Chakravartula, Akhil Ramanujam
    Shen Jincheng
    Beddhu, Srinivasan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
12345